Inovio Starts Phase 2 Trial of VGX-3100 Vaccine for Pre-cancerous Vulvar Lesions
News
Inovio’s Phase 2 trial assessing the effectiveness of VGX-3100 in patients with pre-cancerous lesions of the vulva, or vulvar intraepithelial neoplasia (VIN), has began dosing patients. VGX-3100, a human papilloma virus ... Read more